1. Effects of human plasma components on the activity of lipoprotein lipase: a study of samples from the vipviza trial using isothermal titration calorimetry. (December 2020) Authors: Kovrov, O.; Landfors, F.; Saar-Kovrov, V.; Näslund, U.; Olivecrona, G. Journal: Atherosclerosis Issue: Volume 315(2020) Page Start: e24 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Peroxisome proliferator‐activated receptor γ activation favours selective subcutaneous lipid deposition by coordinately regulating lipoprotein lipase modulators, fatty acid transporters and lipogenic enzymes. (12th March 2016) Authors: Blanchard, P. G.; Turcotte, V.; Côté, M.; Gélinas, Y.; Nilsson, S.; Olivecrona, G.; Deshaies, Y.; Festuccia, W. T. Journal: Acta physiologica Issue: Volume 217:Number 3(2016) Page Start: 227 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Silencing of ANGPTL4 via antisense oligonucleotides effectively reduces plasma triglyceride and glucose levels in mice without causing lymphadenopathy. (August 2022) Authors: Nilsson, S.K.; Deng, M.; Kutrolli, E.; Motamedi, M.; Olivecrona, G.; Kersten, S. Journal: Atherosclerosis Issue: Volume 355(2022) Page Start: 25 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗